Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CTSV | O60911 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22690549 | 0.86 | ALDH1A1 (0.43) | ALDH1A1TDP1CYP3A4HTTMAPT | |
| SCHEMBL22123594 | 0.81 | ALDH1A1 (0.50) | ALDH1A1TDP1CYP3A4ALOX15TP53 | |
| SCHEMBL17758010 | 0.80 | HSD17B10 (0.47) | ALDH1A1TDP1MAPTKMT2AMEN1 | |
| SCHEMBL31613766 | 0.78 | ALDH1A1 (0.47) | ALDH1A1TDP1CYP3A4ALOX15TP53 | |
| SCHEMBL24475959 | 0.77 | ERN1 (0.43) | ALDH1A1MAPTKMT2AMEN1POLB | |
| SCHEMBL28068351 | 0.77 | ALDH1A1 (0.62) | ALDH1A1TDP1CYP3A4ALOX15TP53 | |
| SCHEMBL4224581 | 0.76 | CTSV (0.54) | ALDH1A1TDP1CYP3A4ALOX15TP53 | |
| SCHEMBL2557500 | 0.75 | ALDH1A1 (0.60) | ALDH1A1TDP1CYP3A4ALOX15TP53 | |
| SCHEMBL28428327 | 0.75 | ALDH1A1 (0.60) | ALDH1A1TDP1CYP3A4ALOX15TP53 | |
| SCHEMBL27882095 | 0.75 | ALDH1A1 (0.60) | ALDH1A1TDP1CYP3A4ALOX15TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2026-01-29 | — | — | US | disclosed |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-12-25 | — | — | US | disclosed |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| EP-4622678-A1 | ANTIBODY-DRUG CONJUGATE COMPRISING AN ANTI-GUCY2C ANTIBODY AS WELL AS METHODS OF PRODUCTION AND USES THEREOF | Heidelberg Pharma Research GmbH (DE) | 2025-10-01 | — | — | EP | disclosed |
| US-20250195675-A1 | NEW ANTIBODY-DRUG CONJUGATE AS WELL AS METHODS OF PRODUCTION AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-19 | — | — | US | disclosed |
| WO-2025120090-A1 | ANTIBODY-DRUG CONJUGATE COMPRISING AN ANTI-GUCY2C ANTIBODY AS WELL AS METHODS OF PRODUCTION AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-12 | — | — | WO | disclosed |
| US-20250186606-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-12 | — | — | US | disclosed |
| WO-2025120085-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-12 | — | — | WO | disclosed |
| WO-2022115451-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| EP-3972651-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| EP-3972649-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| EP-3972650-A2 | ANTIBODY DRUG CONJUGATES HAVING LINKERS COMPRISING HYDROPHILIC GROUPS | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| CN-113853219-A | Antibody drug conjugates with linkers comprising hydrophilic groups | 诺华股份有限公司 | 2021-12-28 | — | — | CN | disclosed |
| WO-2020236817-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020236825-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020236841-A2 | ANTIBODY DRUG CONJUGATES HAVING LINKERS COMPRISING HYDROPHILIC GROUPS | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020236825-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020236817-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186606-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | BCR, TBCD, TBC1D5 | ALDH1A1 2138/4885TDP1 3888/4885CYP3A4 4337/4885 |
| US-20250195675-A1 | NEW ANTIBODY-DRUG CONJUGATE AS WELL AS METHODS OF PRODUCTION AND USES THEREOF | GUCY1B2, GUCY1A2, ADCY2 | ALDH1A1 773/4885TDP1 1853/4885CYP3A4 3750/4885 |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPHA2, EPHA1, EPHB1 | ALDH1A1 951/4885TDP1 3222/4885CYP3A4 3236/4885 |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | BID, BCL2, MCL1 | ALDH1A1 4315/4885TDP1 265/4885CYP3A4 4007/4885 |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | MET, BCL3, BCL9 | ALDH1A1 2347/4885TDP1 4095/4885CYP3A4 3014/4885 |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | FCGR2A, FCGR3B, BCL3 | ALDH1A1 3069/4885TDP1 1610/4885CYP3A4 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.